Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 61
1983 80
1984 88
1985 79
1986 114
1987 89
1988 87
1989 139
1990 108
1991 119
1992 97
1993 119
1994 120
1995 108
1996 95
1997 95
1998 91
1999 83
2000 85
2001 96
2002 100
2003 135
2004 191
2005 247
2006 273
2007 259
2008 285
2009 258
2010 227
2011 266
2012 293
2013 194
2014 160
2015 170
2016 186
2017 199
2018 226
2019 208
2020 366
2021 452
2022 372
2023 352
2024 75

Text availability

Article attribute

Article type

Publication date

Search Results

5,967 results

Results by year

Filters applied: . Clear all
Page 1
Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
Chen J, Hu J, Gu L, Ji F, Zhang F, Zhang M, Li J, Chen Z, Jiang L, Zhang Y, Shi R, Ma L, Jia S, Zhang Y, Zhang Q, Liang J, Yao S, Hu Z, Guo Z. Chen J, et al. Cancer Immunol Immunother. 2023 Feb;72(2):409-425. doi: 10.1007/s00262-022-03238-w. Epub 2022 Aug 4. Cancer Immunol Immunother. 2023. PMID: 35925286
Clinical immunotherapy in pancreatic cancer.
Ye X, Yu Y, Zheng X, Ma H. Ye X, et al. Cancer Immunol Immunother. 2024 Mar 2;73(4):64. doi: 10.1007/s00262-024-03632-6. Cancer Immunol Immunother. 2024. PMID: 38430289 Free PMC article. Review.
Cancer immunity and immunotherapy beyond COVID-19.
Bellone M, Brevi A, Bronte V, Dusi S, Ferrucci PF, Nisticò P, Rosato A, Russo V, Sica A, Toietta G, Colombo MP. Bellone M, et al. Cancer Immunol Immunother. 2023 Jul;72(7):2541-2548. doi: 10.1007/s00262-023-03411-9. Epub 2023 Mar 30. Cancer Immunol Immunother. 2023. PMID: 36995489 Free PMC article. No abstract available.
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors.
Sauer N, Janicka N, Szlasa W, Skinderowicz B, Kołodzińska K, Dwernicka W, Oślizło M, Kulbacka J, Novickij V, Karłowicz-Bodalska K. Sauer N, et al. Cancer Immunol Immunother. 2023 Nov;72(11):3405-3425. doi: 10.1007/s00262-023-03516-1. Epub 2023 Aug 11. Cancer Immunol Immunother. 2023. PMID: 37567938 Free PMC article. Review.
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis.
Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, Grande E, Battelli N, Massari F. Santoni M, et al. Cancer Immunol Immunother. 2023 Jun;72(6):1365-1379. doi: 10.1007/s00262-022-03349-4. Epub 2023 Jan 12. Cancer Immunol Immunother. 2023. PMID: 36633661 Review.
5,967 results